Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3848-3854

  Young, Travis W ^a   Rosen, Daniel G ^b   Mei, Fang C ^a   Li, Nan ^a   Liu, Jinsong ^b   Wang, Xiao Fan ^c   Cheng, Xiaodong ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P21; SMALL INTERFERING RNA; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

AGED; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 34447134864     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0337     Document Type: Article

References (50)

1. Maucuer A, Camonis JH, Sobel A. Stathmin interaction with a putative kinase and coiled-coil - forming protein domains. Proc Natl Acad Sci U S A 1995;92:3100-4.
2. Watanabe M, Yanagi Y, Masuhiro Y, et al. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 1998;245:900-5.
3. Koonin EV, Abagyan RA. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 1997;16:330-1.
4. Ponting CP, Cai YD, Bork P. The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med 1997;75:467-9.
5. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG, Lehner PJ. Ubiquitination of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J 2002;21:2418-29.
6. Babst M, Odorizzi G, Estepa EJ, Emr SD. Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 2000;1:248-58.
7. Sundquist WI, Schubert HL, Kelly BN, Hill GC, Holton JM, Hill CP. Ubiquitin recognition by the human TSG101 protein. Mol Cell 2004;13:783-9.
8. Lu Q, Hope LW, Brasch M, Reinhard C, Cohen SN. TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci U S A 2003;100:7626-31.
9. Blot V, Perugi F, Gay B, et al. Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding. J Cell Sci 2004;117:2357-67.
10. Carter CA. Tsg101: HIV-1's ticket to ride. Trends Microbiol 2002;10:203-5.
11. Amit I, Yakir L, Katz M, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev 2004;18:1737-52.
12. Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996;85:319-29.
13. Li L, Li X, Francke U, Cohen SN. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 1997;88:143-54.
14. Li L, Francke U, Cohen SN. Retraction. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 1998;93:661.
15. Lee MP, Feinberg AP. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997;57:3131-4.
16. Gayther SA, Barski P, Batley SJ, et al. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 1997;15:2119-26.
17. Wang Q, Driouch K, Courtois S, et al. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Oncogene 1998;16:677-9.
18. Steiner P, Barnes DM, Harris WH, Weinberg RA. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Genet 1997;16:332-3.
19. Sun Z, Pan J, Bubley G, Balk SP. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 1997;15:3121-5.
20. Wagner KU, Dierisseau P, Rucker EB III, Robinson GW, Hennighausen L. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 1998;17:2761-70.
21. Young TW, Mei FC, Rosen DG, et al. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics 2007;6:294-304.
22. Lee KR, Tavassoli FA, Prat J. Surface epithelial stromal tumors of the ovary and peritoneum. In: Tabassoli FA, Devilee P, editors. WHO classification of tumors, pathology and genetics, tumors of the breast and female genital organs. Washington, D.C.: IARC Press, Lyon; 2003. p.117-61.
23. Benda JA, Zaino R. GOG pathology manual. Buffalo (NY): Gynecologic Oncology Group; 1994.
24. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
25. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
26. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004;17:790-7.
27. Young T, Mei F, Liu J, Bast RC, Jr., Kurosky A, Cheng X. Proteomics analysis of H-RAS - mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 2005;24:6174-84.
28. Zhong Q, Chen CF, Chen Y, Chen PL, Lee WH. Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Cancer Res 1997;57:4225-8.
29. Zhong Q, Chen Y, Jones D, Lee WH. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 1998;58:2699-702.
30. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001;107:55-65.
31. Ismaili N, Blind R, Garabedian MJ. Stabilization of the unliganded glucocorticoid receptor by TSG101. J Biol Chem 2005;280:11120-6.
32. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995;92:5545-9.
33. Ruland J, Sirard C, Elia A, et al. p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc Natl Acad Sci U S A 2001;98:1859-64.
34. Wagner KU, Krempler A, Qi Y, et al. Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 2003;23:150-62.
35. 1-S and p53-independent cell death. J Biol Chem 2002;277:43216-23.
36. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004;64:4577-84.
37. Liu RT, Huang CC, You HL, et al. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 2002;21:4830-7.
38. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004;53:235-40.
39. Zhu G, Gilchrist R, Borley N, et al. Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 2004;109:541-7.
40. Anttila MA, Kosma VM, Hongxiu J, et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 1999;79:1870-8.
41. el Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
42. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
43. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
44. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994;9:3407-15.
45. Zhang W, Grasso L, McClain CD, et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995;55:668-74.
46. Elbendary A, Berchuck A, Davis P, et al. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994;5:1301-7.
47. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
48. Li L, Liao J, Ruland J, Mak TW, Cohen SN. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci U S A 2001;98:1619-24.
49. Carstens MJ, Krempler A, Triplett AA, Van Lohuizen M, Wagner KU. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 2004;279:35984-94.
50. Oh H, Mammucari C, Nenci A, Cabodi S, Cohen SN, Dotto GP. Negative regulation of cell growth and differentiation by TSG101 through association with p21 (Cip1/WAF1). Proc Natl Acad Sci U S A 2002;99:5430-5.